Antiplatelet and anticoagulant use after myocardial infarction

Clinical Cardiology

Volumn 19, Issue 5, 1996, Pages 357-365

  Almony, Gregory T ^a   Lefkovits, Jeffrey ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

antiplatelets; antithrombins; aspirin; GPIIb IIIa; heparin; hirudin; myocardial infarction; warfarin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ILOPROST; MONOCLONAL ANTIBODY; PROSTACYCLIN; RIDOGREL; STREPTOKINASE; SULFINPYRAZONE; THROMBIN INHIBITOR; THROMBOXANE A2; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARACHIDONIC ACID METABOLISM; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0029833423     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190506     Document Type: Review

References (109)

1. Chesebro JH, Badimon JJ, Ortiz AF, Meyer BJ. Fuster V: Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction. Am J Cardiol 72, 66G-74G (1993)
2. Mayne R: Collagenous proteins of blood vessels.Arterioscleosis 6, 585-593 (1986)
3. Stone E: An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc Lond (Biol) 53, 195-200 (1763)
4. Craven LL: Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Med J 75, 38-44 (1953)
5. DeWitt DL, Smith WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85, 1412-1416 (1988)
6. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 330, 1287-1294 (1994)
7. Smith WL: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263, F181-F191 (1992)
8. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72, 2994-2998 (1975)
9. Roth GJ, Calverley DC: Aspirin, platelets, and thrombosis: Theory and practice. Blood 83, 885-898 (1994)
10. Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296, 320-331 (1988)
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet II, 349-360 (1988)
12. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325, 1261-1266 (1991)
13. The SALT Collaborative Group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebro-vascular ischaemic events. Lancet 338, 1345-1349 (1991)
14. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of aspirin: An overview of randomized controlled trials. Br J Clin Pharmac 35, 219-226 (1993)
15. Gershlick AH: Principles of platelet inhibitor therapy - where we stood in 1993. Eur Heart J 15, 149-155 (1994)
16. Kuster LJ, Frohlich JC: Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP, and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 32, 415-423 (1986)
17. The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336, 827-830 (1990)
18. Berglund V, Wallentiin L: Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid in men with unstable coronary artery disease. Eur Heart J 12, 428-433 (1991)
19. Biagent C, Collins R: ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction(abstr). Circulation 88, I-291 (1993)
20. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308, 81-106 (1994)
21. The Persantine-Aspirin Reinfarction Study Research Group: Persantine and aspirin in coronary artery disease. Circulation 62, 449-461 (1980)
22. Grose R, Greenberg M, Strain J, Mueller H, Dyer A: Intracoronary prostacyclin in evolving acute myocardial infarction. Am J Cardiol 55, 1625-1626 (1985)
23. Kiernan FJ, Kluger J, Regnier JC, Rutkowski M, Fieldman A: Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction. Br Heart J 56, 428-432 (1986)
24. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, Kline EM, Pitt B: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol 14, 877-884 (1989)
25. Saltiel E. Ward A: Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 34, 222-262 (1987)
26. Defreyn G, Bernat A, Delebasse P, Maffrand J-P: Pharmacology of ticlopidine: A review. Sem Thromb Hemost 15, 159-166 (1989)
27. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, for the Ticlopidine Aspirin Stroke Study Group: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321, 501-507 (1989)
28. Jordan C, Carvalho H, Fajadet J, Cassagneau B, Robert G, Marco J: Reduction of subacute thrombosis rate after coronary stenting using a new anticoagulant protocol(abstr). Circulation 90, I-125 (1994)
29. Morice M-C, Bourdonnec C, Lefevre T, Blanchard D, Monassier J-P, Lienhart Y, Commeau P, Makowski S, Labrunie P, Cribier A, Joly P: Coronary stenting without coumadin. Phase III(abstr). Circulation 90, I-125 (1994)
30. Blengino S, Maiello L, Hall P, Nakamura S, Martini G, Colombo A: Randomized trial of coronary stent implantation without anticoagulation: Aspirin vs. ticlopidine(abstr). Circulation 90, I-124 (1994)
31. Herbert JM, Bemat A, Sainte-Marie M, Dol F, Rinaldi M: Potentiating effect of clopidogrel and SO 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 69, 268-271 (1993)
32. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 89, 588-595 (1994)
33. Gogstad GO, Brosstad F, Krutnes MB, Hagen I, Solum NO: Fibrinogen binding properties of the human platelet glycoprotein IIb-IIIa complex: A study using crossed radioimmunoelectrophoresis. Blood 60, 663-671 (1982)
34. Parise LV, Phillips DR: Reconstitution of the purified platelet fibrinogen receptor Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem 260, 10698-10707 (1985)
35. Plow EF, Ginsberg MH: GP IIb/IIIa as a prototypic adhesion receptor. In Progress in Hemostasis and Thrombosis (Ed. Coller BS). W.B. Saunders, Philadelphia (1989) 117-156
36. Calvete JJ: Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoprotein IIb/IIIa complex. Thromb Haemost 72, 1-15 (1994)
37. Ginsberg MH, Xiaoping D, O'Toole TE, Loftus JC, Plow EF: Platelet integrins. Thromb Haemost 70, 87-93 (1993)
38. Plow EF, Srouji AH, Meyer D, Marguerie G, Ginsberg MH: Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 259, 5388-5391 (1984)
39. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330, 956-961 (1994)
40. Lefkovits J, Ivanhoe R, Anderson K, Weisman H, Topol EJ, for the EPIC Investigators: Platelet IIb/IIIa receptor inhibition during PTCA for acute myocardial infarction: Insights from the EPIC Trial(abstr). Circulation 90, I-564 (1994)
41. Kleiman NS, Ohman ME, Califf RM, George BS, Keriakes D, Aguirre F, Bates E, Schaible T, Topol EJ: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: Results of the TAMI 8 pilot study. J Am Coll Cardiol 22, 381-389 (1993)
42. Charo IF, Scarborough RM, du Mee CP, Wolf D, Phillips DR, Swift RL: Pharmacodynamics of the GPIIb-IIIa antagonist Integrelin: Phase I clinical studies in normal healthy volunteers(abstr). Circulation 86, I-260 (1992)
43. Song A, Scarborough RM, Phillips DR, Adelman B, Strony J: Integrelin enhances fibrinolysis and prevents acute arterial reocclusion following thrombolysis in a canine anodal current model with high-grade stenosis(abstr). Circulation 86, I-410 (1992)
44. Nicolini FA, Lee P, Rios G, Kotke-Marchant K, Topol EJ: Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 89, 1802-1809 (1994)
45. Ohman M, Kleiman N, Talley D, Gacioch G, Navetta F, Carney R, Worley S, Anderson V, Cohen M, Keriakes D, Joseph D, Sigmon K, Topol E, for the IMPACT-AMI Study Group: Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction(abstr). Circulation 90, I-564 (1994)
46. Lincoff AM, Tcheng JE, Bass TA, Popma JJ, Teirstein PS, Kleiman ND, Weisman HF, Musco MH, Cabot CF, Berdan LG, Califf RM, Topol EJ: A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with platelet GPIIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization (abstr). J Am Coll Cardiol 25, 80A (1995)
47. Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ: Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Cor Art Dis 4, 167-175 (1993)
48. Hirsh J, Fuster V: Guide to anticoagulant therapy, Part 2: Oral anticoagulants. Circulation 89, 1469-1480 (1994)
49. Final Report of the Veterans Administration Cooperative Study: Long-term anticoagulant therapy after myocardial infarction. J Am Med Assoc 207, 2263-2267 (1969)
50. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council: Assessment of short-term anticoagulant administration after cardiac infarction. Br Med J 1, 335-342 (1969)
51. Second Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council: An assessment of long-term anticoagulant administration after cardiac infarction. Br Med J 2, 837-843 (1964)
52. An International Anticoagulant Review Group: Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet 1, 203-209 (1970)
53. Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323, 147-152 (1990)
54. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343, 499-503 (1994)
55. Johannessen KA, Nordrehaug JE, von der Lippe G: Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction. Eur Heart J 8, 975-980 (1987)
56. Keating EC, Gross SA, Schlamowitz RA, Glassman J, Mazur JH, Pitt WA, Miller D: Mural thrombi in myocrdial infarctions. Prospective evaluation by two-dimensional echocardiography. Am J Med 74, 989-995 (1983)
57. Weinreich DJ, Burke JF, Pauletto FJ: Left ventricular mural thrombi complicating acute myocardial infarction. Ann Intern Med 100, 789-794 (1984)
58. Kouvaras G, Chronopoulos G, Soufras G, Sofronas G, Solomos D. Bakirtzes A, Pissimissis E, Tzonou A, Cokkinos D: The effects of long-term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction. Am Heart J 119, 73-78 (1990)
59. Theroux P, Lidon R-M: Anticoagulants and their use in acute ischemic syndromes. In Textbook of Interventional Cardiology (Ed. Topol E). W.B. Saunders Co.. Philadelphia (1993) 23-45
60. Breddin K, Loew D, Lechner K, Oberla K, Walter E: The German-Austrian Aspirin Trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 62, v63-v72 (1980)
61. The Enquête de Prévention Secondaire de l'Infarctus du Myocarde (E.P.S.I.M.) Research Group: A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 307, 701-708 (1982)
62. Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, van der Pol JMJ, van Eenige MJ: Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 87, 1524-1530 (1993)
63. White HD, French JK, Hamer AW, Brown MA, Williams BF. Ormiston JA, Cross DB: Frequent reocclusion of patent infarctrelated arteries between 4 weeks and 1 year Effects of antiplatelet therapy. J Am Coll Cardiol 25, 218-223 (1995)
64. Report of the Sixty Plus Reinfarction Study Research Group: A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2, 989-993 (1980)
65. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C, for the Antithrombotic Therapy in Acute Coronary Syndromes (ATACS) Research Group: Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS Trial. Circulation 89, 81-88 (1994)
66. McLean J: The thromboplastic action of cephalin. Am J Physiol 41, 250-257 (1916)
67. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part I: Heparin. Circulation 89, 1449-1468 (1994)
68. Rosenberg RD, Bauer KA: The heparin-antithrombin system: A natural anticoagulant mechanism. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Eds. Colman R, Hirsh J, Marder V, Salzman E). JB Lippincott Co., Philadelphia (1994) 837-860
69. Tollefsen DM, Majerus DW, Blank MK: Heparin cofactor II: Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 257, 2162-2169 (1982)
70. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336, 65-71 (1990)
71. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339, 753-770 (1992)
72. Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JMJ, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJM. Cohen AF: Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86, 1370-1375 (1992)
73. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329, 673-682 (1993)
74. Hsia J, Kleinman N, Aguirre F, Chaitman BR, Roberts R, Ross AM, for the HART Investigators: Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. J Am Coll Cardiol 20, 31-35 (1992)
75. de Bono DP, Simoons JL, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M, for the European Cooperative Study Group: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomized double blind European Cooperative Study Group trial. Br Heart J 67, 122-128 (1992)
76. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL: Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66, 1412-1417 (1990)
77. LATE Study Group: Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 342, 759-766 (1993)
78. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee LK, Ellis SG, Califf RM, and the TAMI Study Group: A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79, 281-286 (1989)
79. Granger CB, Califf RM, Hirsh J, Woodlief LH, Topol EJ, for the GUSTO Investigators: APTTs after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age. and sex: Experience from the GUSTO trial(abstr). Circulation 86, I-1027 (1992)
80. Antman EM, for the TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report form the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90, 1624-1630 (1994)
81. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90, 1631-1637 (1994)
82. Thompson PL, Aylward PE, Federman J, Giles RW, Harris PJ, Hodge RL, Nelson GIC, Thomson A, Tonkin AM, Walsh WF, for the National Heart Foundation of Australia Coronary Thrombolysis Group: A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 83, 1534-1542 (1991)
83. Flynn M, Werth D, Gudipati R, Pedersen W, Serota H, Johnson W, Gibson P, Hamilton W, Morton D, Changlani M, Armbruster R, Stonner T, Al-Joundi B, Lewen M, Aquirre F, for the rt-PA Heparin Duration Trial Investigators: Influence of heparin duration on coronary angiographic characteristics in patients receiving accelerated weight-adjusted rt-PA dosing for acute myocardial infarction(abstr). Circulation 88, I-201 (1993)
84. Deutsch E, Rao AK, Colman RW: Selective thrombin inhibitors: The next generation of anticoagulants. J Am Coll Cardiol 22, 1089-1092 (1993)
85. Schmid JH, Jackson DP, Conley CI: Mechanism of action of thrombin on platelets. J Clin Invest 41, 543-553 (1962)
86. Loscalzo J, MeInick B, Handin RI: The interaction of platelet factor 4 and glycosoaminoglycans. Arch Biochem Biophys 240, 446-455 (1985)
87. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86, 385-391 (1990)
88. Bell WR, Tomasulo PA, Alving BM, Duffy TP: Thrombocytopenia occurring during the administration of heparin: A prospective study of 52 patients. Ann Intern Med 85, 155-160 (1976)
89. Bell WR, Royall RM: Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J Med 303, 902-907 (1980)
90. Powers PJ, Cuthbert D, Hirsh J: Thrombocytopenia found uncommonly during heparin therapy. J Am Med Assoc 241, 2396-2397 (1979)
91. Warkentin TE, Kelton JG: Heparin-induced thrombocytopenia. Ann Rev Med 40, 31-44 (1989)
92. Hogg PJ, Jackson CM: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci 86, 3619-3623 (1989)
93. Eisenberg PR, Sherman LA, Jaffe AS: Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 10, 527-529 (1987)
94. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A: Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 79, 980-989 (1989)
95. Gulba DC, Barthels M, Reil GH, Lichtlen PR: Thrombin/antithrombin III complex level as early predictor of reocclusion after successful thrombolysis (letter). Lancet 2, 97 (1988)
96. Hirsh J, Levine MN: Low molecular weight heparin. Blood 79, 1-17 (1992)
97. Markwardt F: Hirudin and derivatives as anticoagulant agents. Thromb Haemost 66, 141-152 (1991)
98. Markwardt F: Untersuchungen über Hirudin. Naturwissenschaften 42, 537-538 (1955)
99. Markwardt F: Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 15, 269-282 (1989)
100. Krstenansky JL, Mao SJT: Antithrombin properties of the C-terminus of hirudin using synthetic unsultated N-a-acetyl-hirudin. FEBS Lett 211, 10-16 (1987)
101. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL: Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095-7101 (1990)
102. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Backer RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23, 993-1003 (1994)
103. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J: Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial. Circulation 89, 1557-1566 (1994)
104. Lidon R-M, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to strepto-kinase in acute myocardial infarction. Circulation 89, 1567-1572 (1994)
105. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardio 21, 1039-1047 (1993)
106. Tabata H, Mizuno K, Miyamoto A, Etsuda H, Isojima K, Satomura K, Shibuya T, Arakawa K, Kurita A, Nakamura H: The effect of a new thrombin inhibitor (Argatroban) in the prevention of reocclusion after reperfusion therapy in patients with acute myocardial infarction(abstr). Circulation 86, I-260 (1992)
107. Neuhaus K-L, van Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 90, 1638-1642 (1994)
108. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH: Athersclerotic plaque rupture and thrombosis: Evolving concepts. Circulation 82, II-47-59 (1990)
109. Grutter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR: Crystal structure of thrombin-hirudin complex: A novel mode of serine protease inhibition. EMBO Journal 9, 2361-2365 (1990)